These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15212862)

  • 1. The cerivastatin withdrawal crisis: a "post-mortem" analysis.
    Maggini M; Raschetti R; Traversa G; Bianchi C; Caffari B; Da Cas R; Panei P
    Health Policy; 2004 Aug; 69(2):151-7. PubMed ID: 15212862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Jamal SM; Eisenberg MJ; Christopoulos S
    Am Heart J; 2004 Jun; 147(6):956-65. PubMed ID: 15199341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cerivastatin withdrawal on statin persistence.
    Reaume KT; Erickson SR; Dorsch MP; Dunham NL; Hiniker SM; Prabhakar N; Kline-Rogers EM; Eagle KA
    Ann Pharmacother; 2008 Jul; 42(7):956-61. PubMed ID: 18523235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.
    Mantel-Teeuwisse AK; Klungel OH; Egberts TC; Verschuren WM; Porsius AJ; de Boer A
    Drug Saf; 2004; 27(1):63-70. PubMed ID: 14720086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].
    Sparing R; Sellhaus B; Noth J; Block F
    Nervenarzt; 2003 Feb; 74(2):167-71. PubMed ID: 12596018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.
    Ozdemir O; Boran M; Gökçe V; Uzun Y; Koçak B; Korkmaz S
    Angiology; 2000 Aug; 51(8):695-7. PubMed ID: 10959522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
    Kind AH; Zakowski LJ; McBride PE
    WMJ; 2002; 101(7):53-6. PubMed ID: 12426921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].
    Huić M; Anić B; Cikes N; Bosnić D; Sentić M; Markeljević J; Mayer M; Pazanin L
    Lijec Vjesn; 2002; 124(3-4):73-6. PubMed ID: 18956824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].
    Sirvent AE; Cabezuelo JB; Enríquez R; Amorós F; González C; Reyes A
    Nefrologia; 2001; 21(5):497-500. PubMed ID: 11795020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myotoxicity and rhabdomyolisis due to statins].
    Banga JD
    Ned Tijdschr Geneeskd; 2001 Dec; 145(49):2371-6. PubMed ID: 11770264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients.
    Nichols GA; Koro CE
    Clin Ther; 2007 Aug; 29(8):1761-70. PubMed ID: 17919557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case reports of rhabdomyolysis associated with cerivastatin therapy.
    Simpson S
    Arch Intern Med; 2001 Nov; 161(21):2630-1. PubMed ID: 11718617
    [No Abstract]   [Full Text] [Related]  

  • 16. Other reports of cerivastatin-induced rhabdomyolysis.
    Gabay M; Lodolce A
    Arch Intern Med; 2001 Nov; 161(21):2629. PubMed ID: 11718614
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
    Psaty BM; Furberg CD; Ray WA; Weiss NS
    JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Another report of acute rhabdomyolysis following cerivastatin monotherapy.
    Milionis HJ; Tsapoga TG; Elisaf MS
    Arch Intern Med; 2001 Nov; 161(21):2629-30. PubMed ID: 11718615
    [No Abstract]   [Full Text] [Related]  

  • 19. Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen.
    Marsà Carretero M; Alos Manrique C; Valles Callol JA
    Br J Gen Pract; 2002 Mar; 52(476):235-6. PubMed ID: 12030671
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk factors for statin-associated rhabdomyolysis.
    Schech S; Graham D; Staffa J; Andrade SE; La Grenade L; Burgess M; Blough D; Stergachis A; Chan KA; Platt R; Shatin D
    Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):352-8. PubMed ID: 16892458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.